Mumbai: Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM), along with its subsidiaries, has officially launched Pertuza, a pertuzumab biosimilar, in India.
The newly introduced therapy is designed for the treatment of HER2-positive breast cancer, a form of cancer that affects thousands of women across the country each year.
The Pertuza biosimilar is an indigenously developed and manufactured product that provides an affordable alternative to the innovator drug.
Also Read: Alkem Foundation Establishes Radiotherapy Centre in North Bihar with INR 100 Cr Investment
In pivotal phase 3 clinical trials, the biosimilar demonstrated equivalence in terms of efficacy, safety, and immunogenicity, meeting stringent regulatory standards.
Access to Pertuza
For Indian patients, access to pertuzumab has historically been restricted due to its high cost, limiting treatment options for many women.
With the introduction of Pertuza, Alkem aims to bridge this gap by offering a treatment that combines affordability, scientific credibility, and widespread accessibility through its oncology distribution network.
Also Read: K-Dense Beta Outperforms GPT-5 in Bioinformatics Benchmark Tests
Commenting on the launch, Dr Vikas Gupta, Chief Executive Officer, Alkem, said: “Breast cancer is the most common cancer among Indian women. Addressing its increasing burden requires treatment solutions that are both effective and affordable. Oncology remains a priority for Alkem, and with Pertuza, we reaffirm our commitment to delivering high-quality therapies that expand access to care for thousands of women each year.”
The launch of Alkem Pertuza biosimilar further strengthens Alkem’s oncology portfolio, which already includes key biosimilars such as cetuximab, denosumab, bevacizumab, and romiplostim.
